RESIST- 1 og RESIST- 2 er igangværende, randomiserede, ublindede multicenterforsøg med HIV- positive, tidligere triple- behandlede patienter, der vurderer behandling med APTIVUS givet sammen med lavdosis ritonavir (500 mg/ 200 mg to gange daglig) plus en optimeret baggrundsbehandling, der defineres individuelt for hver enkelt patient ud fra genotypisk resistens- test og patientens anamnese.
RESIST-1 and RESIST-2 are ongoing, randomised, open-label, multicentre studies in HIV-positive, triple-class experienced patients, evaluating treatment with APTIVUS co-administered with low dose ritonavir (500 mg/ 200 mg twice daily) plus an optimised background regimen (OBR) individually defined for each patient based on genotypic resistance testing and patient history.